Kiromic Biopharma

About:

Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.

Website: http://kiromic.com

Twitter/X: Kiromic1

Description:

Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Their cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.

Total Funding Amount:

$63.2M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Houston, Texas, United States

Founded Date:

2012-01-01

Contact Email:

customerservice(AT)kiromic.com

Founders:

Maurizio Chiriva-Internati

Number of Employees:

51-100

Last Funding Date:

2022-10-27

IPO Status:

Public

Industries:

© 2025 bioDAO.ai